Stock SUMMIT THERAPEUTICS PLC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Summit Therapeutics plc London S.E.

Equities

GB00BN40HZ01

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Akebia Therapeutics, Inc. Appoints Erik Ostrowski as Senior Vice President and Chief Business Officer
CI
Akebia Therapeutics, Inc. Appoints Erik Ostrowski as Chief Financial Officer
CI
Summit Therapeutics Inc. announced that it has received $199.999998 million in funding from Baker Bros. Advisors LP
CI
Summit Therapeutics Inc. Announces Resignation of Ujwala Mahatme as Member of its Board
CI
Sector Update: Health Care Stocks Steady Premarket Monday
MT
Stifel Adjusts Summit Therapeutics Price Target to $14 From $8, Maintains Buy Rating
MT
Transcript : Summit Therapeutics Inc. - Special Call
Summit Therapeutics Generates $200 Million Through Share Sale; Expand License Territories for Ivonescimab
MT
Summit Raises $200 Million; Also Expands License Territories for Ivonescimab
BU
Summit Therapeutics Inc. Expands License Territories for Ivonescimab
CI
Summit Therapeutics Inc. announced that it expects to receive $199.999998 million in funding from Baker Bros. Advisors LP
CI
Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
BU
 Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
BU
Sector Update: Health Care Stocks Flat to Higher Pre-Bell Friday
MT
Wall Street Set to Open Modestly Higher Friday as Key Inflation Data Meets Expectations
MT
Sector Update: Health Care
MT
US Futures Trend Modestly Lower Pre-Bell Friday as Investors Await Key Inflation Report
MT
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Health Care Stocks Steady -- Health Care Roundup
DJ
Summit Therapeutics Inc. Announces Phase III Clinical Trial, HARMONI-2 or AK112-303 Met its Primary Endpoint of Progression-Free Survival
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SMMT Stock
  4. Stock
  5. News Summit Therapeutics plc